We are live on ! Find out more
AMLX icon

Amylyx Pharmaceuticals
AMLX

171 hedge funds and large institutions have $1.59B invested in Amylyx Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 62 increasing their positions, 53 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

503% more call options, than puts

Call options by funds: $9.02M | Put options by funds: $1.5M

17% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 53

17% more capital invested

Capital invested by funds: $1.36B → $1.59B (+$230M)

1.02% more ownership

Funds ownership: 102.24% → 103.27% (+1%)

4% less funds holding

Funds holding: 179 → 171 (-8)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

19% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 36

Holders
171
Holders Change
-8
Holders Change %
-4.47%
% of All Funds
2.1%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.06%
New
29
Increased
62
Reduced
53
Closed
36
Calls
$9.02M
Puts
$1.5M
Net Calls
+$7.52M
Net Calls Change
+$2.34M

Top Buyers

1
SL
Siren LLC
Connecticut
+$17.3M
2
Franklin Resources
Franklin Resources
California
+$14.9M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$11M
4
Barclays
Barclays
United Kingdom
+$9.52M
5
JAM
Jupiter Asset Management
United Kingdom
+$8.12M

Top Sellers

1
SI
Sofinnova Investments
California
-$6.37M
2
SCM
Silverarc Capital Management
Massachusetts
-$6.12M
3
Ameriprise
Ameriprise
Minnesota
-$6.07M
4
PSC
Patient Square Capital
California
-$4.23M
5
NCM
Nantahala Capital Management
Connecticut
-$4.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
101
Parsons Capital Management
Rhode Island
$301K – – –
BNP Paribas Financial Markets
102
BNP Paribas Financial Markets
France
$294K -$57.1K -4,061 -16%
VIA
103
Virtus Investment Advisers
Connecticut
$289K +$7.15K +508 +3%
PPWP
104
Premier Path Wealth Partners
New Jersey
$282K – – –
Brown Advisory
105
Brown Advisory
Maryland
$277K – – –
HT
106
Headlands Technologies
Illinois
$275K -$151K -10,729 -35%
CUAMC
107
China Universal Asset Management Company
China
$271K +$22.4K +1,593 +9%
ProShare Advisors
108
ProShare Advisors
Maryland
$252K -$41K -2,914 -14%
ASRS
109
Arizona State Retirement System
Arizona
$252K -$67.7K -4,815 -21%
Creative Planning
110
Creative Planning
Kansas
$249K +$252K +17,883 New
VIA
111
Vanguard Investments Australia
Australia
$246K +$249K +17,713 New
KK
112
KLP Kapitalforvaltning
Norway
$242K – – –
PA
113
Profund Advisors
Maryland
$238K -$48.3K -3,437 -17%
SFCM
114
Seven Fleet Capital Management
California
$232K +$71.7K +5,100 +44%
VOYA Investment Management
115
VOYA Investment Management
Georgia
$212K -$281 -20 -0.1%
Prudential Financial
116
Prudential Financial
New Jersey
$196K +$199K +14,120 New
Verition Fund Management
117
Verition Fund Management
Connecticut
$184K -$228K -16,223 -55%
Amundi
118
Amundi
France
$179K +$181K +12,895 New
Royal Bank of Canada
119
Royal Bank of Canada
Ontario, Canada
$172K -$45.9K -3,260 -21%
LCM
120
Landscape Capital Management
New Jersey
$170K – – –
HSBC Holdings
121
HSBC Holdings
United Kingdom
$157K +$161K +11,414 New
PR
122
PSP Research
Pennsylvania
$151K -$470K -33,385 -75%
Pictet Asset Management
123
Pictet Asset Management
Switzerland
$150K +$151K +10,768 New
Victory Capital Management
124
Victory Capital Management
Texas
$148K +$1.29K +92 +0.9%
GLA
125
Great Lakes Advisors
Illinois
$144K +$146K +10,380 New
3 4
5
6 7

AMLX Hedge Fund Activity: Q1 2026 in Review

171 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q1 2026, worth a combined $1.59B — up 17% from $1.36B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of AMLX and 29 opened new positions — a net loss of 7 holders — while 53 trimmed existing stakes and 62 added.

The largest buyer was Siren LLC, opening a new position worth an estimated $17.3M. The largest seller was Sofinnova Investments, exiting entirely with an estimated $6.37M sold.

  • 171 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q1 2026, down from 179 in Q4 2025.
  • Funds reported $1.59B of Amylyx Pharmaceuticals stock for Q1 2026, up 17% quarter-over-quarter.
  • 29 funds opened new Amylyx Pharmaceuticals positions in Q1 2026 and 36 closed out, a net change of -7 holders.
  • The largest Amylyx Pharmaceuticals buyer in Q1 2026 was Siren LLC, an estimated $17.3M added.
  • The largest Amylyx Pharmaceuticals seller in Q1 2026 was Sofinnova Investments, an estimated $6.37M sold.

Based on aggregated 13F filings for Q1 2026.